FDA Orders Warnings About Sudden Blindness for Erectile Dysfunction Medication Labels

Main Category: Erectile Dysfunction / Premature Ejaculation
Article Date: 12 Jul 2005 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


FDA officials on Friday ordered that labels for erectile dysfunction medications must include warnings about a potential link with sudden blindness but said that the agency has not confirmed a causal relationship between the treatments and the condition, the... AP/Boston Herald reports (AP/Boston Herald, 7/8). In a statement, FDA officials said that certain men -- those who are older than age 50, smoke and have high blood pressure, heart disease or high cholesterol -- have a higher risk for nonarteritic anterior ischemic optic neurophathy, which is caused by an interruption of blood flow to the nerve that links the eye to the brain. However, FDA officials said that that they could not "determine whether these oral medicines for erectile dysfunction were the cause of the loss of eyesight or whether the problem is related to other factors such as high blood pressure or diabetes or to a combination of these problems" (Kauffman, Washington Post, 7/9). FDA officials also said that patients who take or plan to take ED medications should inform their physicians if they have experienced severe vision loss (Wall Street Journal, 7/11).

Reaction
Joseph Feczko -- chief medical officer for Pfizer, which manufactures the ED medication Viagra -- said, "There is no evidence that Viagra causes blindness or any other serious ocular condition." Sen. Chuck Grassley (R-Iowa), who has said that an FDA safety officer asked the agency to require warnings about a potential link between ED medications and NAION more than 13 months earlier, said, "It shouldn't take bad publicity to get the FDA to act on the advice of its own scientists and do everything it can to inform and protect the public." He added, "Why did it take more than a year in this case? Did the FDA spend time negotiating label changes with the drug industry and, as a result, withhold vital drug-safety information from millions of patients and their doctors?" (Washington Post, 7/9). NPR's "NPR News" on Saturday reported on the FDA order (Silberner, "NPR News," NPR, 7/9).

The complete segment is available online in RealPlayer.

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Viagra.


Article adapted by Medical News Today from original press release.
Visit our erectile dysfunction / premature ejaculation section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kieth HadSmith. "FDA Orders Warnings About Sudden Blindness for Erectile Dysfunction Medication Labels." Medical News Today. MediLexicon, Intl., 12 Jul. 2005. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/27280.php>

APA
Kieth HadSmith. (2005, July 12). "FDA Orders Warnings About Sudden Blindness for Erectile Dysfunction Medication Labels." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/27280.php.

Please note: If no author information is provided, the source is cited instead.


Erectile Dysfunction / Premature Ejaculation

Most Popular Articles





Follow Our Erectile Dysfunction News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Erectile Dysfunction / Premature Ejaculation Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »